Fentiazac
Appearance
Clinical data | |
---|---|
Trade names | Norvedan |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.038.129 |
Chemical and physical data | |
Formula | C17H12ClNO2S |
Molar mass | 329.80 g·mol−1 |
3D model (JSmol) | |
Melting point | 162–163 °C (324–325 °F) |
| |
| |
(what is this?) (verify) |
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.[2]
Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.[3]
See also
[edit]References
[edit]- ^ Lombardino JG (1985). Nonsteroidal antiinflammatory drugs. Vol. 247. New York: Wiley. p. 285. ISBN 978-0-471-89803-0.
- ^ Brown K, Cater DP, Cavalla JF, Green D, Newberry RA, Wilson AB (November 1974). "Nonsteroidal antiinflammatory agents. 1.2,4-Diphenylthiazole-5-acetic acid and related compounds". Journal of Medicinal Chemistry. 17 (11): 1177–1181. doi:10.1021/jm00257a010. PMID 4414839.
- ^ "FENTIAZAC". NCATS Inxight Drugs. National Center for Advancing Translational Sciences (NCATS); U.S. National Institutes of Health. Retrieved 2023-06-08.